Advanced Cell Technology Announces Release of New Edition of Definitive Resource in Tissue Engineering
Widely-recognized publication in tissue engineering co-edited by ACT’s Chief Scientific Officer Robert Lanza, M.D.
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., and Robert Langer, Sc.D., Koch Institute Professor at MIT and Scientific Chair of ACT’s Board of Directors, have released the fourth edition of “Principles of Tissue Engineering” (Academic Press/Elsevier), the widely-recognized definitive resource in the field of tissue engineering. The 1936-page volume includes contributions from 20 members of the National Academies of Science, Engineering, and Institute of Medicine, as well as dozens of pioneers in the fields of stem cells, tissue engineering, and regenerative medicine.
Principles of Tissue Engineering, Fourth Edition, follows three very successful editions published since in 1997. The first edition was the first comprehensive body of work dedicated entirely to the tissue engineering field. The volume quickly became the most relevant textbook in the tissue engineering arena. Now, 16 years later, major advances have occurred, with entirely new classes of stem cells being described. Progress in the field has been so rapid, that since publication of the last edition of the book, the first clinical trials have been carried out using human embryonic stem cells (hESCs). Last year, the first paper reporting results of patients treated with hESCs was published by ACT and its collaborators.
The Fourth Edition of “Principles” covers all of this recent progress as well as the latest advances in the biology and design of tissues and organs, from mathematical models to clinical reality. The book combines the prerequisites for a general understanding of tissue growth and development, the tools needed to design tissues and organs, as well as a presentation by the world’s experts of what is currently known about each specific organ system. “Principles” strikes a balance among the diversity of subjects that are related to tissue engineering, including biology, chemistry, and engineering, while also emphasizing those research areas that are likely to be of clinical value in the future. This new edition includes greatly expanded focus on stem cells, including iPS cells and stem cell niches. This up-to-date coverage of stem cell biology and other emerging technologies is complemented by a series of new chapters on recent clinical experience in applying tissue engineering, as well as a new section on the application of tissue-engineering for food production. The result is a comprehensive textbook that should be useful to students and experts alike.
In addition to Drs. Lanza and Langer, Principles 4E was co-edited by Joseph Vacanti, M.D., John Homans Professor of Surgery and Director, Laboratory for Tissue engineering and Organ Fabrication at Harvard Medical School and Massachusetts General Hospital.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, the relevance and applicability of clinical trials in animals to studying the effect of products in humans, future growth in animal and human research and development programs, potential new applications of and expanded indications covering our technology, the effects of donorless sources of stem cells on potency and the risk of communicable diseases in the manufacturing context, the existence and size of potential or existing market opportunities for the company, the effect of the company’s products on the medical needs and quality of life of pets, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for and limited sources of future capital, failures or delays in obtaining regulatory approval of products, risks inherent in the development and commercialization of potential products, reliance on new and unproven technology in the development of products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the Quarterly Report on Form 10-Q for the three months ended June 30, 2013. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
Russo Partners
David Schull, 212-845-4271
Widely-recognized publication in tissue engineering co-edited by ACT’s Chief Scientific Officer Robert Lanza, M.D.
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., and Robert Langer, Sc.D., Koch Institute Professor at MIT and Scientific Chair of ACT’s Board of Directors, have released the fourth edition of “Principles of Tissue Engineering” (Academic Press/Elsevier), the widely-recognized definitive resource in the field of tissue engineering. The 1936-page volume includes contributions from 20 members of the National Academies of Science, Engineering, and Institute of Medicine, as well as dozens of pioneers in the fields of stem cells, tissue engineering, and regenerative medicine.
Principles of Tissue Engineering, Fourth Edition, follows three very successful editions published since in 1997. The first edition was the first comprehensive body of work dedicated entirely to the tissue engineering field. The volume quickly became the most relevant textbook in the tissue engineering arena. Now, 16 years later, major advances have occurred, with entirely new classes of stem cells being described. Progress in the field has been so rapid, that since publication of the last edition of the book, the first clinical trials have been carried out using human embryonic stem cells (hESCs). Last year, the first paper reporting results of patients treated with hESCs was published by ACT and its collaborators.
The Fourth Edition of “Principles” covers all of this recent progress as well as the latest advances in the biology and design of tissues and organs, from mathematical models to clinical reality. The book combines the prerequisites for a general understanding of tissue growth and development, the tools needed to design tissues and organs, as well as a presentation by the world’s experts of what is currently known about each specific organ system. “Principles” strikes a balance among the diversity of subjects that are related to tissue engineering, including biology, chemistry, and engineering, while also emphasizing those research areas that are likely to be of clinical value in the future. This new edition includes greatly expanded focus on stem cells, including iPS cells and stem cell niches. This up-to-date coverage of stem cell biology and other emerging technologies is complemented by a series of new chapters on recent clinical experience in applying tissue engineering, as well as a new section on the application of tissue-engineering for food production. The result is a comprehensive textbook that should be useful to students and experts alike.
In addition to Drs. Lanza and Langer, Principles 4E was co-edited by Joseph Vacanti, M.D., John Homans Professor of Surgery and Director, Laboratory for Tissue engineering and Organ Fabrication at Harvard Medical School and Massachusetts General Hospital.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, the relevance and applicability of clinical trials in animals to studying the effect of products in humans, future growth in animal and human research and development programs, potential new applications of and expanded indications covering our technology, the effects of donorless sources of stem cells on potency and the risk of communicable diseases in the manufacturing context, the existence and size of potential or existing market opportunities for the company, the effect of the company’s products on the medical needs and quality of life of pets, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for and limited sources of future capital, failures or delays in obtaining regulatory approval of products, risks inherent in the development and commercialization of potential products, reliance on new and unproven technology in the development of products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the Quarterly Report on Form 10-Q for the three months ended June 30, 2013. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.
Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
Russo Partners
David Schull, 212-845-4271
